

Review Article

Pathophysiology and Management Chronic Heart Failure

Gudisa Bereda 

Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia, **ORCID ID:** <https://orcid.org/0000-0002-5982-9601>

***Corresponding Author:** Gudisa Bereda

Department of Pharmacy, Negelle Health Science College, Guji, Ethiopia

Article History

Received: 19.03.2022

Accepted: 21.04.2022

Published: 06.05.2022

Abstract: Chronic heart failure refers to a clinical state of systemic and pulmonary congestion resulting from inability of the heart to pump as much blood as required for the adequate metabolism of the body. The commonest causes of heart failure are coronary artery disease, hypertension and diabetes, however, hypertension and diabetes have been found to be stronger risk factors in elderly women and coronary artery disease and smoking are stronger risk factors in elderly men. Pathophysiologically, heart failure is either an inadequate cardiac output for the organism's metabolic demands or an adequate cardiac output that is due to neurohormonal compensation, which means the inability of the heart to supply blood to the tissues according to their needs without additional strain. The pharmacological treatment of chronic heart failure with reduced ejection fraction is now based on four classes of drugs that have been proven to reduce mortality among heart failure patients such as angiotensinogen converting enzyme inhibitors or angiotensin II receptor blockers, beta-blockers, aldosterone antagonists and sodium-glucose co-transporter 2 inhibitors. Angiotensinogen converting enzyme inhibitors or angiotensin II receptor blocker therapy should be initiated at a low dose with very gradual up titration, monitoring renal function and serum potassium levels closely. Chronic heart failure treatment with direct inhibitors of aldosterone receptors brought about a significant improvement in terms of survival and hospitalizations.

Keywords: Chronic heart failure; Pathophysiology; Management.

INTRODUCTION

Chronic heart failure, a clinical syndrome in which abnormalities of ventricular function and neurohormonal regulation lead to pulmonary venous congestion, exercise intolerance, and decreased life expectancy, remains the one major cardiovascular disorder that has increased both in incidence and prevalence in recent years [1]. Chronic heart failure (CHF) induces change in the molecular architecture of the myocardium. Consequently, contractility and synchronicity of systolic and diastolic function are compromised, posing significant problems when metabolic demand is increased. Optimal cardiac function during exercise is dependent on an ability to increase heart rate and contractility, to compensate for decreased filling time of the left ventricle, which ultimately reduces stroke volume [2, 3]. Heart failure affects around 26 million people worldwide and around 50% of patients die within 5 years of diagnosis [4]. A broad array of biological pathways contributes to the development and progression of heart failure (HF), including neurohormonal and remodeling mechanisms. In addition to being a syndrome encompassing activation of cardiovascular disease-related mechanisms, heart failure may also be viewed as a systemic disorder with alterations to metabolism, immune response, haemostasis/ fibrinolysis, and iron homeostasis [5-7]. Chronic heart failure (CHF) is a significant and growing health-care challenge, as increasing numbers of people live longer and survive ischaemic heart disease [8]. Heart failure is characterised by cardiomyocyte energy depletion due to mitochondrial dysfunction and adenosine triphosphate depletion, leading to abnormal calcium handling and impaired contractile function [9]. One of the most prevalent diseases worldwide is chronic heart failure (CHF). It is linked with low quality of life and notable morbidity/mortality [10, 11]. Chronic heart failure (CHF) incidence and prevalence increases with age. Heart failure (HF) is a leading cause of hospitalization and accounts for approximately 7% of cardiovascular deaths [12]. Currently, approximately 64.3

Copyright © 2022 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

Citation: Gudisa Bereda (2022) Pathophysiology and Management Chronic Heart Failure. *South Asian Res J Bio Appl Biosci*, 4(2), 26-36.

million people in the world are suffering from cardiac insufficiency; its increase in incidence over the past three decades could be assigned to significant changes in the demographics of the world population, HF management, and the incidence and survival of illnesses predisposing to HF [13-15].

Etiological factors

The commonest causes of HF are coronary artery disease (CAD), hypertension and diabetes, however, hypertension and diabetes have been found to be stronger risk factors in elderly women and CAD and smoking are stronger risk factors in elderly men. The concomitant diseases such as atrial fibrillation, valvular heart disease, diabetes, chronic kidney disease, arrhythmias, anemia, chronic obstructive pulmonary disease (COPD), depression, thyroid pathologies, congenital cardiomyopathies, inflammatory diseases and excessive alcohol intake, obesity, arthritis, sensory impairment, and cognitive dysfunction substantially add to the complexity of HF care. It has been shown that 2/3 of elderly patients with HF have more than two non-cardiac co-morbidities and over 25% of them have more than six comorbidities [16-18].

Pathophysiology

Heart failure (HF) is the pathophysiological state in which the heart is unable to pump blood at a rate commensurate with the requirements of metabolizing tissues, or can do so only from an elevated filling pressure. A complex series of neurohormonal changes takes place as a result of the two principal haemodynamic alterations occurring in this condition: reduction of cardiac output and atrial hypertension. In the early stages of acute systolic failure, these changes are heightened adrenergic drive, activation of the renin angiotensin aldosterone axis, and augmented release of vasopressin and endothelin are truly compensatory, maintaining perfusion to vital organs and increasing the inadequate arterial blood volume. As HF becomes chronic, several of these compensatory mechanisms can cause undesirable effects such as excessive vasoconstriction, increased afterload, excessive retention of salt and water, electrolyte abnormalities, and arrhythmias [19-21]. Exercise intolerance at both maximal and submaximal effort is the hallmark of progressive heart failure, and it is associated with worsened quality of life and increased risk of adverse clinical outcomes. Two extracardiac factors (“peripheral factors”) abnormal metabolic vasodilation in skeletal muscle and abnormal skeletal muscle substrate use in the pathogenesis of exercise intolerance at maximal and submaximal effort in patients with chronic systolic heart failure have its role [22, 23]. Submaximal exercise endurance capacity is determined by factors that link oxygen delivery, substrate use, and ventilation in response to increased metabolic demand during exercise. In patients with chronic systolic heart failure, available evidence suggests that submaximal exercise is limited not by reduced nutritive blood flow, but rather by impaired substrate use in skeletal muscle. Patients with chronic heart failure demonstrate reduced percentage of type I (oxidative slow-twitch) muscle fibers, reduced skeletal muscle aerobic enzyme activity, reduced skeletal muscle mitochondrial volume density, reduced skeletal muscle mass, and reduced skeletal muscle mitochondrial oxidative capacity independent of nutrient blood flow when compared with control populations. Endurance performance at submaximal exercise levels is determined by the efficiency of mitochondrial conversion of oxygen to adenosine triphosphate and efficiency of the conversion of adenosine triphosphate to physical work. Decreased work efficiency during submaximal exercise has been reported in subjects with chronic systolic heart failure when compared with control subjects without heart failure [24-27].




Figure 1: Pathophysiology of exercise intolerance in patients with chronic systolic heart failure

A combination of hemodynamic factors related to impaired cardiac pump function (reduced cardiac output reserve, neurohormonal activation, and increased cardiac filling pressures) and extracardiac factors that limit skeletal muscle oxygen use (impaired metabolic vasodilation, reduced skeletal muscle mass, and mitochondrial dysfunction) contribute to impairment of both submaximal and maximal exercise capacity in patients with chronic systolic heart failure.

Excess interstitial fibrosis is an important detrimental aspect of chronic LVH and chronic heart failure (CHF). Oxidative stress is well known to be pro-fibrotic in many organs, and recent work suggests that nicotinamide adenine dinucleotide phosphate 2 (Nox2) oxidase-derived ROS are centrally involved in the development of interstitial cardiac fibrosis. A similar inhibition of interstitial fibrosis was found in a model of aldosterone infusion, either in Nox2 knockout mice or in animals treated with nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor, apocynin. Interstitial cardiac fibrosis was also inhibited in Nox2 knockout mice subjected to aortic banding. Multiple underlying mechanisms are likely to be involved in these Nox2-dependent pro-fibrotic effects, including increased expression of pro-fibrotic growth factors and genes, increased activation of nuclear factor KB (NF- κ B), activation of matrix metalloproteinases, and inflammatory cell infiltration [28, 29]. Cytokines form a vast array of relatively low molecular weight, pharmacologically active proteins. These substances are secreted by different cell types for the purpose of altering either their own function (autocrine) or that of adjacent cells (paracrine). The most important cytokines implicated in the progression of CHF are tumour necrosis factor α (TNF α), interleukin (IL) 1, and IL-6. These cytokines share some of their major characteristics (redundancy), and all act in a proinflammatory sense [30].

Nitric Oxide

Nitric oxide (NO) is a lipophilic, freely diffusible, soluble gas, which has a short half-life of less than four seconds in biological solutions. Its nearly ubiquitous involvement has resulted in an explosion in the NO field in the last years. NO is produced from the amino acid L-arginine by nitric oxide synthase (NOS), and it reacts with O₂ in aqueous solutions yielding the relatively inert nitrate (NO₃) and nitrite (NO₂). However, NO also reacts with oxygen derived free radicals, namely superoxide anion, to form the toxic peroxynitrite (ONOO₂). NO is produced by a group of well characterised isoforms of nitric oxide synthase (NOS). Three isoforms have been identified. (1) The endothelial (constitutive) isoform (eNOS, also known as NOS₃) produces a continuous amount of NO, which acts as a vasodilator. In endothelial cells, eNOS is mainly found in the membrane of caveolae, small invaginations, which are characterised by the presence of a marker protein termed caveolin. After synthesis in the endothelium, NO diffuses across the cell membrane and enters vascular smooth muscle cells to induce muscle relaxation [31, 32].

Tumour necrosis factor α

TNF α is associated observed that mean (SEM) serum concentrations of TNF α were higher in CHF patients than in healthy subjects. They also demonstrated that those patients with high concentrations of TNF α were more often suffering from cardiac cachexia. TNF α exerts its effects via TNF α receptors (TNFR), which are expressed by almost all nucleated cells. Two TNFRs have so far been identified. TNFR-1 is more abundantly expressed and appears to be the main signalling receptor. The majority of deleterious effects caused by TNF α seem to be mediated via this receptor, whereas TNFR-2 appears to have a more protective role in the heart. Proteolytic cleavage by TNF α converting enzyme (TACE) yields the soluble forms. The role of soluble TNFRs is sometimes to stabilize the TNF α molecule, thus potentiating its detrimental long term actions. However, higher concentrations of TNFRs appear to inhibit TNF α activity. It is thought that high plasma concentrations of soluble TNFRs primarily indicate a history of raised TNF α values. The reproducibility of plasma concentrations of soluble TNFRs is higher than that of TNF α itself. This may be the reason why soluble TNFRs predict short term and long term prognosis better than TNF α in CHF patients [33-35].

Natriuretic Peptides

Both are released in response to pressure or volume overload means ANP and BNP plasma concentrations are elevated in patients with heart failure. It balances the effects of the RAAS by causing natriuresis, diuresis, vasodilation, decreased aldosterone release, decreased hypertrophy, and inhibition of the SNS and RAAS [34].

C Reactive Protein

C reactive protein (CRP) was so named because it reacts with the somatic C polysaccharide of *Streptococcus pneumoniae*. CRP specifically binds to specific microbial polysaccharides (phosphocholine moieties), which gives this substance a host defensive role. Upon binding to these structures, CRP activates the classical complement pathway and opsonises ligands for phagocytosis. CRP is exclusively produced in the liver. It is secreted in increased amounts within six hours of an inflammatory stimulus and is therefore regarded as a marker of acute inflammation [36].

Renin- angiotensin aldosterone system

The RAA system is activated in patients with heart failure. Similar to the sympathetic nervous system, initial activation may be important to maintain cardiac output in a damaged heart by increasing preload through sodium

retention and volume expansion. Perfusion also may be maintained by vasoconstriction [37]. Angiotensin II Effects of ATII are mediated by the activation of specific angiotensin receptors, AT1 and AT2. Both receptors have high affinity for ATII but are functionally distinct. They are located throughout the body including the kidneys, brain, endothelium, and heart. Binding of ATII to AT1 and AT2 receptors may produce biologic effects that may be important to the pathophysiology of heart failure. The AT1 receptor-signaling pathway interacts with both adenylate cyclase and the G protein system. Stimulation of the AT1 receptor causes activation of several phospholipases, leading to an increase in inositol 1,4,5 triphosphate, which stimulates intracellular calcium release and vasoconstriction [38-40].

Aldosterone

Aldosterone may play a significant role in the pathophysiology of heart failure that goes beyond sodium and water retention. Circulating or plasma concentrations of aldosterone are produced in the adrenals. Angiotensin II stimulation of the AT1 receptor increases aldosterone secretion, although other mechanisms also may do this, such as plasma potassium, adrenocorticotrophic hormone, and endothelin, and decreased metabolic clearance [41].




Figure 2: The mechanism by which renin-angiotensin-aldosterone system cause heart failure

Diagnostic Criteria

Heart failure is usually associated with dyspnoea, fatigue, and fluid retention. Symptoms alone cannot be relied on in making the diagnosis: a careful history and physical examination need to be supplemented by further tests. Diagnosis requires consideration of the underlying abnormality of the heart, the severity of the syndrome, the aetiology, the precipitating and exacerbating factors, the identification of concomitant disease relevant to management, and an estimation of prognosis. The following investigations should be carried out in a patient with suspected heart failure: Twelve lead electrocardiography (check chamber hypertrophy, low-voltage QRS morphologic characteristics with ST-T wave abnormalities may suggest myocardial inflammatory disease or pericarditis) ; Chest radiography (check cardiac enlargement, increased pulmonary vascular bed); Blood biochemistry (including urea, creatinine, glucose, electrolytes), haemoglobin, thyroid and liver function tests, and blood lipids; Urinalysis to detect proteinuria or glycosuria; Cardiac imaging usually a transthoracic echocardiogram, which can rapidly provide detailed information about the structure and function of the cardiac chambers, valves, and pericardium; Hyponatremia: serum sodium <130 mEq/L; Serum creatinine may be increased due to hypoperfusion [42, 43].

HF classification

Many clinical classification systems have been proposed to classify severity of HF and guide patient management. The most popular system is the New York Heart Association (NYHA) classification that ranges from essentially asymptomatic patients (NYHA I) to mild (NYHA II, slight limitation in physical activity), moderate (NYHA III, symptoms on light exercise) and severe HF (NYHA IV, breathless at rest. The staging system is meant to complement, not replace, the widely used New York Heart Association (NYHA) classification, which is organized according to severity of symptoms. The latter remains useful because severity of symptoms has a robust correlation with survival and quality of life [44].

Table 1: NYHA classes focus on exercise capacity and symptoms of HF

NYHA class	Degree of clinical impairment
I	No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue and palpitations
II	Slight limitation of physical activity. Comfortable at rest but, ordinary physical activity results in undue breathlessness, fatigue and palpitations
III	Marked limitation of physical activity. Comfortable at rest but, less than ordinary physical activity results in undue breathlessness, fatigue and palpitations
IV	Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken discomfort is increased

The updated ACC/AHA guidelines for evaluating and managing HF include a new, four-stage classification system emphasizing the progression of the disease. The new guidelines include patients with “preclinical” stages of HF with the hope of slowing (and perhaps reversing) progression of disease. The ACC/AHA classification system recognizes the progressive course of HF and identifies those at risk, reinforcing the importance of neurohormonal antagonism in an attempt to arrest disease progression [45].




Figure 3: Stage and treatment of chronic heart failure

Management

Modern treatment aims to control symptoms and prolong life by blocking the neurohormonal activation and controlling the fluid retention. Goal of therapy are improve quality of life, relieve or reduce symptoms, treating underlying cause, prevent or minimize hospitalizations, slow disease progression, and prolong survival [46].

Lifestyle management

Lifestyle changes can have an important impact. Ready to cook meals and convenience foods contain large amounts of salt and may increase the dose of diuretic needed to control fluid retention. All patients should be discouraged from adding salt to their food and should try to reduce the amount of salt they add during cooking. Severe salt restriction (< 2 g/day) is rarely necessary. Regular aerobic exercise should be encouraged, as it improves peripheral muscle function and exercise tolerance in patients with heart failure. If alcohol is the cause of the heart failure then abstinence is essential. Smoking cessation should be encouraged. Restrictions on activities within the context of the specific diagnosis and the patient's ability, cardiac rehabilitation, restriction of fluid and sodium intake, infection prevention, weight monitoring and competitive and strenuous sports activities are usually contraindicated [47]. Self-management is integral to achieving best patient outcomes: to reduce mortality and improve quality of life. Self-management in CHF usually involves behavioural adaptation. Patients may need to learn new behaviours, such as learning how to monitor and manage symptoms and complex medical regimens. Patients may also need to abstain (e.g. cease smoking), adapt (e.g. restrict

their sodium, cholesterol and fluid intake) and maintain (e.g. exercise regularly) other behaviours. While targets have been recommended for best CHF management practice (such as to restrict fluid to 1.5 litres per day and to monitor weight changes > 2 kgs over three days), these need to be individualized according to the patient symptom and disease status profile and reset regularly [48].

Pharmacological Treatment

Pharmacology needs to be carefully selected for a multitude of reasons. First, there are physiological age-related changes that influence drug pharmacokinetics and pharmacodynamics. Ageing is also associated with a change in body composition, which results in a lower volume of distribution and higher plasma concentrations of hydrophilic drugs, while the plasma concentrations of lipophilic drugs tend to decrease. Second, these patients often have multiple other comorbidities which increases the risk of drug side effects (renal, liver dysfunction, orthostatic hypotension) and conflicts with HF treatment guidelines e.g., angiotensin-converting enzyme inhibitors (ACEI) with orthostatic hypotension. The presence of cognitive impairment makes treatment compliance more challenging and is a marker of poorer outcome. Polypharmacy also increases the risk of drug-drug interactions. Patients with CHF, on average take 10 medications with significant risk for adverse drug reactions. Third the presence of social and economic issues, frailty and caregiver burden needs all to be taken into account when choosing a plan management. The pharmacological treatment of chronic HFrEF is now based on four classes of drugs that have been proven to reduce mortality among HF patients such as ACE inhibitors or angiotensin II receptor blockers (ARBs), beta-blockers, aldosterone antagonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors (SGLT2-inhibitors) [49-53].

Diuretics

Mechanism of actions: Decrease reabsorption of water and sodium by the kidney; decrease circulating blood volume; decrease pulmonary fluid overload and ventricular filling pressure.

Diuretics have been found to be of major importance for symptomatic treatment and maintenance of euvolemia. Diuretics are the most effective means of removing fluid retention, and their introduction often produces rapid symptomatic relief. Diuretics should be prescribed in all patients with symptoms/signs of pulmonary or systemic congestion. The mainstay for managing the symptoms of fluid overload is diuretics. Loop diuretic inhibit a specific ion transport protein, the Na⁺-K⁺-2Cl⁻ symporter on the apical membrane of renal epithelial cells in the ascending limb of the loop of Henle [54, 55].

Angiotensinogen converting enzyme inhibitors/Angiotensin II receptor blockers

ACEIs have cardiac remodeling function independent of after load reducing effect, reduced morbidity and mortality in adult patients and aldosterone reducing effect which decrease in retention of sodium and water. ACE inhibitors improve symptoms, slow disease progression, and decrease mortality in patients with HF and reduced LVEF. ACE inhibitors should also be used to prevent the development of HF in at-risk patients. ARBs are used only in patient's stage A, B, or C HF who are intolerant of ACEIs. Candesartan and valsartan are FDA-approved for HF and are the preferred agents. ACEI or angiotensin receptor blocker (ARB) therapy should be initiated at a low dose with very gradual up titration, monitoring renal function and serum potassium levels closely. CHF treatment with direct inhibitors of aldosterone receptors brought about a significant improvement in terms of survival and hospitalizations. Small increases in the serum creatinine level (0.5 mg/mL) do not mandate discontinuation of ACEI or ARB but should prompt careful assessment of volume status and consideration of a reduction in diuretic dosages [56-58].

Beta-blockers

β-blockers slow disease progression, decrease hospitalizations, and reduce mortality in patients with HF. use of β-blockers in all stable patients with HF and a reduced LVEF in the absence of contraindications. β-Blockers are also recommended for asymptomatic patients with a reduced LVEF (stage B) to decrease the risk of progression to HF. β-blockers should be started in very low doses with slow upward dose titration. Metoprolol CR/XL, carvedilol, Nebivolol and bisoprolol are the only β-blockers shown to reduce mortality in large HF trials. Beta-blockers have shown to improve survival by 26% and 49% (low dose and high dose respectively) if added to an ACEI by improving LV function [59].

Digoxin

Mechanism of actions: Inhibition of the sodium-potassium adenosine triphosphatase (Na⁺/K⁺ ATPase) pump-rise in intracellular calcium (Ca⁺⁺) and sodium (Na⁺) coupled with the loss of intracellular potassium (K⁺), increased force of myocardial muscle contraction net positive inotropic effect, increases the automaticity of Purkinje fibers but slows conduction through the atrioventricular (AV) node. Digoxin has positive inotropic effects, but its benefits in HF are related to its neurohormonal effects. Attenuates the excessive SNS activation and Improving impaired baroreceptor function. Digoxin does not improve survival in HF patients. Digoxin is indicated as an adjunct for rate control in atrial fibrillation and for HF with advanced systolic dysfunction as an inotropic agent in New York Heart Association (NYHA) class III or IV. While it may improve function and quality of life, it does not impact survival [60].

Spironolactone

There are benefits to the use of aldosterone antagonists for treatment of systolic HF. Low doses (not more than 25 mg/d) are recommended in patients with severe systolic HF without significant renal dysfunction [contraindicated in chronic kidney disease (CKD) stage 4 and 5 not on dialysis]. Inhibits aldosterone and enhances potassium retention, dose is 2-3mg/kg/24hrs in 2-3 divided doses and improve survival in patients with advanced heart failure *via* a mechanism that is independent of diuresis [61, 62].

Statins

Statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) block the rate limiting step in cholesterol biosynthesis in the liver and other tissues. These drugs are administered orally, are well tolerated, and generally safe. It has been reported that statins can improve the prognosis of coronary artery disease irrespective of serum cholesterol values, which gave rise to the idea that effects beyond cholesterol lowering so called pleiotropic effects exist. Indeed, some substances from this group have been shown to improve endothelial function by inducing cNOS gene transcription. Some statins might be able to reduce vascular production of reactive oxygen species. Moreover, statins have been found to reduce C reactive protein values after myocardial infarction and in hypercholesterolaemia. Moreover, statins might decrease the production of TNF α , IL-1, and IL-6 from macrophages [63, 64]. Quality of life and exercise capacity increased significantly in the statin-treated patients. In addition, there was a trend towards increased LVEF and improved endothelial function [65].

B-type natriuretic peptide

The cardiac-derived natriuretic peptide BNP and its related peptides may be such markers. Given that myocardial stretch stimulates BNP production and release, that the heart is the major source of BNP, and that BNP can easily be measured in plasma, there is a straightforward rationale for evaluating circulating BNP as a biomarker for cardiac overload [66].

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors (Empagliflozin) has glucuretic, diuretic and natriuretic properties, which means that through SGLT inhibition, it decreases blood glucose, causes osmotic diuresis and reduces sodium load. Approximately 80 g of glucose is excreted every day due to SGLT2 inhibition if the patient maintains normal renal functions. As SGLT2-inhibitors work in the proximal tubules, they increase the delivery of fluid and electrolytes to the macula densa, which activates tubuloglomerular feedback leading to afferent glomerular arteriole vasoconstriction. This result in a reduction in intraglomerular hypertension, diminishes glomerular hyperfiltration, attenuates albuminuria and thereby decelerates the progression of diabetic as well as non-diabetic chronic kidney disease. Although a decrease in eGFR may be initially observed during empagliflozin treatment, it is followed by stabilization after a longer period of time. Empagliflozin treatment is associated with many beneficial effects, such as weight loss despite increased food intake, largely due to body fat loss, improvement of endothelial dysfunction and arterial stiffness, reduction in blood pressure in diabetic patients and alleviation of the early signs of nephropathy in diabetic animal models; on the other hand, empagliflozin preserved body weight in models of type 1 diabetes. Patients with type 2 diabetes were observed to have lost weight and reduced their blood pressure, as well as improved glycemic control after undergoing empagliflozin treatment in monotherapy or as an addition to other medication [67-70]. Empagliflozin causes osmotic diuresis and reduces both intravascular and interstitial volume; thus it can cause symptomatic hypotension, especially in patients on hypotensive drugs, the elderly, patients with renal impairment and patients with low systolic blood pressure. SGLT2-inhibitors may interact with loop diuretics commonly used in patients with HF; thus, an adjustment of doses is required [71].

Nitrates and hydralazine

Reduce systemic vascular resistance (SVR) and increase stroke volume and cardiac output. They also provide additional benefits by interfering with the biochemical processes associated with HF progression. Improve mortality, hospitalizations for HF, and quality of life in African-Americans who receive standard therapy. The combination is also appropriate as first-line therapy in patients unable to tolerate ACEIs or ARBs [72].

Alpha and beta adrenergic agonists

They are usually given in an intensive care setting. Long term use may increase morbidity and mortality

Dopamine: β agonist predominantly but has α agonist effect at higher doses. Less chronotropic and arrhythmogenic and selective renal vasodilation

Dobutamine: Dopamine derivative, have direct inotropic effect and moderate reduction of PVR. It can be used in adjunct with dopamine eliminate vasoconstrictive effect and less risk of rhythm disturbance [73].

Cardiac Surgery

Heart transplantation can transform a very sick patient, but owing to the shortage of donor organs and the general level of comorbidity in many patients with heart failure this is not an option for the vast majority. Xenotransplantation using a genetically modified pig heart remains a distant prospect. The design of implantable mechanical assist devices is improving, and these provide a “bridge” to transplantation or may tide a patient over until recovery from myocarditis. Some patients have survived several years with such devices [74].

CONCLUSION

Chronic heart failure (CHF) incidence and prevalence increases with age. Heart failure (HF) is a leading cause of hospitalization and accounts for approximately 7% of cardiovascular deaths. The pathophysiology of chronic systolic heart failure is fundamentally determined by the failure of the circulatory system to deliver sufficient oxygen for metabolic needs, and it is best explained by a complex interplay between intrinsic abnormalities of ventricular pump function and extra cardiac factors that limit oxygen use in metabolically active tissues. Modern treatment aims to control symptoms and prolong life by blocking the neurohormonal activation and controlling the fluid retention. Diuretics have been found to be of major importance for symptomatic treatment and maintenance of euvolemia. Diuretics are the most effective means of removing fluid retention, and their introduction often produces rapid symptomatic relief.

Abbreviations

ACEI: Angiotensinogen converting enzyme inhibitors; ARB: Angiotensin receptor blocker; BNP: B-type natriuretic peptide; CAD: Coronary artery disease; CHF: Chronic heart failure; COPD: Chronic obstructive pulmonary disease; eGFR: Estimated glomerular filtration rate; HFrEF: Heart failure with reduced ejection fraction; IL: Interleukin; LVH: Left ventricular hypertrophy; LVEF: Left ventricular ejection fraction; NF-KB: Nuclear factor-kB; NYHA: New York Heart Association; NADPH: Nicotinamide adenine dinucleotide phosphate; iNOS: Inducible nitric oxide synthase; ROS: Reactive oxygen species; SGLT2-inhibitors: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors; TNFa: Tumour necrosis factor a;

ACKNOWLEDGMENTS

The author would be grateful to anonymous reviewers by the comments that increase the quality of this manuscript.

Data Sources: Sources searched include Google Scholar, Research Gate, PubMed, NCBI, NDSS, PMID, PMCID, Scopus database, Scielo and Cochrane database. Search terms included: pathophysiology and management of chronic heart failure

Funding: None.

Availability of data and materials: The datasets generated during the current study are available with correspondent author.

Competing interests: The author has no financial or proprietary interest in any of material discussed in this article.

REFERENCES

1. Alem, M. M., Alshehri, A. M., Alshehri, M. A., AlElaiw, M. H., Almaa, A. A., & Bustami, R. T. (2022). Red Blood Cell Distribution Width (RDW) in Chronic Heart Failure: Does it have a Prognostic Value in Every Population?. *Electronic Journal of General Medicine*, 19(1), 338.
2. Nguyễn, U. C., Verzaal, N. J., van Nieuwenhoven, F. A., Vernooij, K., & Prinzen, F. W. (2018). Pathobiology of cardiac dyssynchrony and resynchronization therapy. *EP Europace*, 20(12), 1898-1909.
3. Obokata, M., Olson, T. P., Reddy, Y. N., Melenovsky, V., Kane, G. C., & Borlaug, B. A. (2018). Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction. *European heart journal*, 39(30), 2810-2821.
4. Shanks, J., Abukar, Y., Lever, N. A., Pachon, M., LeGrice, I. J., Crossman, D. J., ... & Ramchandra, R. (2022). Reverse remodelling chronic heart failure by reinstating heart rate variability. *Basic Research in Cardiology*, 117(1), 1-16.
5. Klimczak-Tomaniak, D., de Bakker, M., Bouwens, E., Akkerhuis, K. M., Baart, S., Rizopoulos, D., ... & Kardys, I. (2022). Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study). *Scientific reports*, 12(1), 1-10.
6. Cresci, S., Pereira, N. L., Ahmad, F., Byku, M., de Las Fuentes, L., Lanfear, D. E., ... & American Heart Association Council on Genomic and Precision Medicine; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. (2019). Heart failure in the era of precision medicine: a scientific statement from the American Heart Association. *Circulation: Genomic and Precision Medicine*, 12(10), e000058.

7. Sakuma, M., Toyoda, S., Arikawa, T., Koyabu, Y., Kato, T., Adachi, T., ... & Inoue, T. (2022). Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial. *PLoS one*, *17*(1), e0261445.
8. Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & Zannad, F. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. *New England Journal of Medicine*, *383*(15), 1413-1424.
9. Ter Maaten, J. M., Voors, A. A., Damman, K., van der Meer, P., Anker, S. D., Cleland, J. G., ... & de Borst, M. H. (2018). Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. *International journal of cardiology*, *253*, 84-90.
10. Alhabeeb, W., Elasfar, A., AlBackr, H., AlShaer, F., Almasood, A., Alfaleh, H., ... & AlHabib, K. F. (2017). Clinical characteristics, management and outcomes of patients with chronic heart failure: results from the heart function assessment registry trial in Saudi Arabia (HEARTS-chronic). *International Journal of Cardiology*, *235*, 94-99.
11. Dauriz, M., Mantovani, A., Bonapace, S., Verlato, G., Zoppini, G., Bonora, E., & Targher, G. (2017). Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. *Diabetes care*, *40*(11), 1597-1605.
12. Filippatos, G., Anker, S. D., Agarwal, R., Ruilope, L. M., Rossing, P., Bakris, G. L., ... & FIGARO-DKD Investigators. (2022). Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. *Circulation*, *145*(6), 437-447.
13. Kowalska, K., Walczak, J., Femlak, J., Młynarska, E., Franczyk, B., & Rysz, J. (2021). Empagliflozin—A New Chance for Patients with Chronic Heart Failure. *Pharmaceuticals*, *15*(1), 47.
14. Groenewegen, A., Rutten, F. H., Mosterd, A., & Hoes, A. W. (2020). Epidemiology of heart failure. *European journal of heart failure*, *22*(8), 1342-1356.
15. Komorowska, A., & Lelonek, M. (2020). Heart failure with preserved ejection fraction: the challenge for modern cardiology. *Folia Cardiologica*, *15*(6), 407-412.
16. Pilling, L. C., Atkins, J. L., Duff, M. O., Beaumont, R. N., Jones, S. E., Tyrrell, J., ... & Melzer, D. (2017). Red blood cell distribution width: genetic evidence for aging pathways in 116,666 volunteers. *PLoS One*, *12*(9), e0185083.
17. Mirkov, I., Popov Aleksandrov, A., Demenesku, J., Ninkov, M., Mileusnic, D., Kataranovski, D., & Kataranovski, M. (2017). Warfarin affects acute inflammatory response induced by subcutaneous polyvinyl sponge implantation in rats. *Cutaneous and ocular toxicology*, *36*(3), 283-288.
18. Kawasoe, S., Kubozono, T., Ojima, S., Miyata, M., & Ohishi, M. (2018). Combined assessment of the red cell distribution width and B-type natriuretic peptide: a more useful prognostic marker of cardiovascular mortality in heart failure patients. *Internal Medicine*, 9846-17.
19. McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., ... & Kathrine Skibellund, A. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *European heart journal*, *42*(36), 3599-3726.
20. Nashawi, M., Sheikh, O., Battisha, A., Mir, M., & Chilton, R. (2022). Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction. *Heart Failure Reviews*, *27*(1), 219-234.
21. Savarese, G., & Lund, L. H. (2017). Global public health burden of heart failure. *Cardiac failure review*, *3*(1), 7-11.
22. Sokos, G. G., & Raina, A. (2020). Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan. *Vascular Health and Risk Management*, *16*, 41.
23. Skrzypek, A., Mostowik, M., Szeliga, M., Wilczyńska-Golonka, M., Dębicka-Dąbrowska, D., & Nessler, J. (2018). Chronic heart failure in the elderly: still a current medical problem. *Folia Medica Cracoviensia*, *58*(4), 47-56.
24. Elgendy, I. Y., Mahtta, D., & Pepine, C. J. (2019). Medical therapy for heart failure caused by ischemic heart disease. *Circulation research*, *124*(11), 1520-1535.
25. Iyngkaran, P., Liew, D., Neil, C., Driscoll, A., Marwick, T. H., & Hare, D. L. (2018). Moving from heart failure guidelines to clinical practice: gaps contributing to readmissions in patients with multiple comorbidities and older age. *Clinical Medicine Insights: Cardiology*, *12*, 1179546818809358.
26. Badu-Boateng, C., Jennings, R., & Hammersley, D. (2018). The therapeutic role of ivabradine in heart failure. *Therapeutic Advances in Chronic Disease*, *9*(11), 199-207.
27. Seferovic, P. M., Ponikowski, P., Anker, S. D., Bauersachs, J., Chioncel, O., Cleland, J. G., ... & Coats, A. J. (2019). Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. *European journal of heart failure*, *21*(10), 1169-1186.
28. Książczyk, M., & Lelonek, M. (2020). Angiotensin receptor/neprilysin inhibitor—a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings. *Heart Failure Reviews*, *25*(3), 393-402.
29. McMahon, S. R., Ades, P. A., & Thompson, P. D. (2017). The role of cardiac rehabilitation in patients with heart disease. *Trends in cardiovascular medicine*, *27*(6), 420-425.
30. Fernandez-Fernandez, B., Sarafidis, P., Kanbay, M., Navarro-González, J. F., Soler, M. J., Górriz, J. L., & Ortiz, A. (2020). SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. *Clinical kidney journal*, *13*(5), 728-733.

31. Kohler, S., Zeller, C., Iliev, H., & Kaspers, S. (2017). Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I–III clinical trials. *Advances in therapy*, 34(7), 1707-1726.
32. Michel, M. C., Mayoux, E., & Vallon, V. (2015). A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. *Naunyn-Schmiedeberg's archives of pharmacology*, 388(8), 801-816.
33. Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., ... & Lachin, J. M. (2018). How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. *Diabetes care*, 41(2), 356-363.
34. Pabel, S., Wagner, S., Bollenberg, H., Bengel, P., Kovacs, A., Schach, C., ... & Sossalla, S. (2018). Empagliflozin directly improves diastolic function in human heart failure. *European journal of heart failure*, 20(12), 1690-1700.
35. Wanner, C., & Marx, N. (2018). SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. *Diabetologia*, 61(10), 2134-2139.
36. Gonzalez, D. E., Foresto, R. D., & Ribeiro, A. B. (2020). SGLT-2 inhibitors in diabetes: a focus on renoprotection. *Revista da Associação Médica Brasileira*, 66, s17-s24.
37. Vallon, V., & Thomson, S. C. (2017). Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. *Diabetologia*, 60(2), 215-225.
38. Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., ... & Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. *New England Journal of Medicine*, 385(16), 1451-1461.
39. Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., ... & Badimon, J. J. (2019). Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. *Journal of the American College of Cardiology*, 73(15), 1931-1944.
40. Patorno, E., Pawar, A., Franklin, J. M., Najafzadeh, M., Déruaz-Luyet, A., Brodovicz, K. G., ... & Schneeweiss, S. (2019). Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPRISE study. *Circulation*, 139(25), 2822-2830.
41. Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & Zannad, F. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. *New England Journal of Medicine*, 383(15), 1413-1424.
42. Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., ... & Packer, M. (2020). SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *The Lancet*, 396(10254), 819-829.
43. Verma, S., McGuire, D. K., & Kosiborod, M. N. (2020). Two tales: one story: EMPEROR-reduced and DAPA-HF. *Circulation*, 142(23), 2201-2204.
44. McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., ... & Langkilde, A. M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. *New England Journal of Medicine*, 381(21), 1995-2008.
45. Solomon, S. D., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., ... & McMurray, J. J. (2021). Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. *European journal of heart failure*, 23(7), 1217-1225.
46. Volpe, M., & Patrono, C. (2021). The EMPEROR-Preserved study: end of the search for the “Phoenix” or beginning of a new season for trials in heart failure with preserved ejection fraction. *Eur Heart J*, 42, 4621-4623.
47. Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., ... & McMurray, J. J. (2018). Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. *European journal of heart failure*, 20(5), 853-872.
48. Triposkiadis, F., Xanthopoulos, A., Bargiota, A., Kitai, T., Katsiki, N., Farmakis, D., Skoularigis, J., Starling, R. C., & Iliodromitis, E. (2021). Diabetes mellitus and heart failure. *J Clin Med*, 10, 3682.
49. Patel, P. A., Liang, L., Khazanie, P., Hammill, B. G., Fonarow, G. C., Yancy, C. W., ... & Hernandez, A. F. (2016). Antihyperglycemic medication use among Medicare beneficiaries with heart failure, diabetes mellitus, and chronic kidney disease. *Circulation: Heart Failure*, 9(7), e002638.
50. McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., ... & Kathrine Skibellund, A. (2021). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *European heart journal*, 42(36), 3599-3726.
51. Chu, L., Fuller, M., Jervis, K., Ciaccia, A., & Abitbol, A. (2021). Prevalence of chronic kidney disease in type 2 diabetes: The Canadian Registry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) study. *Clinical Therapeutics*, 43(9), 1558-1573.
52. Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., ... & Filippatos, G. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *New England Journal of Medicine*, 383(23), 2219-2229.
53. Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., ... & Ruilope, L. M. (2021). Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *New England Journal of Medicine*, 385(24), 2252-2263.
54. Ruilope, L. M., Agarwal, R., Anker, S. D., Bakris, G. L., Filippatos, G., Nowack, C., ... & FIGARO-DKD study investigators. (2019). Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. *American journal of nephrology*, 50(5), 345-356.
55. Bozkurt, B., Coats, A. J., Tsutsui, H., Abdelhamid, C. M., Adamopoulos, S., Albert, N., ... & Zieroth, S. (2021). Universal definition and classification of heart failure: a report of the heart failure Society of America, heart failure association of the European Society of cardiology, Japanese heart failure Society and writing Committee of the universal definition of heart

- failure: endorsed by the Canadian heart failure Society, heart failure association of India, cardiac Society of Australia and New Zealand, and Chinese heart failure association. *European Journal of Heart Failure*, 23(3), 352-380.
56. Birkeland, K. I., Bodegard, J., Eriksson, J. W., Norhammar, A., Haller, H., Linszen, G. C., ... & Kadowaki, T. (2020). Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. *Diabetes, obesity and metabolism*, 22(9), 1607-1618.
 57. Zareini, B., Blanche, P., D'Souza, M., Elmegaard Malik, M., Nørgaard, C. H., Selmer, C., ... & Lamberts, M. (2020). Type 2 diabetes mellitus and impact of heart failure on prognosis compared to other cardiovascular diseases: a nationwide study. *Circulation: Cardiovascular Quality and Outcomes*, 13(7), e006260.
 58. Urbich, M., Globe, G., Pantiri, K., Heisen, M., Bennison, C., Wirtz, H. S., & Di Tanna, G. L. (2020). A systematic review of medical costs associated with heart failure in the USA (2014–2020). *Pharmacoeconomics*, 38(11), 1219-1236.
 59. Deswal, A. (2019). Heart failure with reduced ejection fraction and renal dysfunction: Beta-blockers Do not disappoint. *Journal of the American College of Cardiology*, 74(23), 2905-2907.
 60. Rangaswami, J., Bhalla, V., Blair, J. E., Chang, T. I., Costa, S., Lentine, K. L., ... & American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. (2019). Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation*, 139(16), e840-e878.
 61. Bereda, G. (2021). Antihypertensive Medications: Explanation, Mechanisms of Action, Adverse Drug Reaction, and Drug Interaction. *International Journal of Chemical and Lifesciences*, 10(5), 2131-2144.
 62. Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021). Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. *Circulation*, 143(11), 1157-1172.
 63. McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z., Dagogo-Jack, S., ... & Cannon, C. P. (2021). Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. *JAMA cardiology*, 6(2), 148-158.
 64. Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., ... & Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. *New England Journal of Medicine*, 385(16), 1451-1461.
 65. Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & Zannad, F. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. *New England Journal of Medicine*, 383(15), 1413-1424.
 66. McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., ... & Langkilde, A. M. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. *New England Journal of Medicine*, 381(21), 1995-2008.
 67. Jankowski, J., Floege, J., Fliser, D., Böhm, M., & Marx, N. (2021). Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. *Circulation*, 143(11), 1157-1172.
 68. Cao, T. H., Jones, D. J., Voors, A. A., Quinn, P. A., Sandhu, J. K., Chan, D. C., ... & Ng, L. L. (2020). Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. *European journal of heart failure*, 22(1), 70-80.
 69. Dubin, R. F., Whooley, M., Pico, A., Ganz, P., Schiller, N. B., & Meyer, C. (2018). Proteomic analysis of heart failure hospitalization among patients with chronic kidney disease: The Heart and Soul Study. *PLoS one*, 13(12), e0208042.
 70. Stenemo, M., Nowak, C., Byberg, L., Sundström, J., Giedraitis, V., Lind, L., ... & Ärnlöv, J. (2018). Circulating proteins as predictors of incident heart failure in the elderly. *European Journal of Heart Failure*, 20(1), 55-62.
 71. Brankovic, M., Akkerhuis, K. M., Mouthaan, H., Brugts, J. J., Manintveld, O. C., van Ramshorst, J., ... & Kardys, I. (2018). Cardiometabolic biomarkers and their temporal patterns predict poor outcome in chronic heart failure (Bio-SHiFT study). *The Journal of Clinical Endocrinology & Metabolism*, 103(11), 3954-3964.
 72. van Boven, N., Battes, L. C., Akkerhuis, K. M., Rizopoulos, D., Caliskan, K., Anroedh, S. S., ... & Kardys, I. (2018). Toward personalized risk assessment in patients with chronic heart failure: detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study. *American heart journal*, 196, 36-48.
 73. Klimczak-Tomaniak, D., Bouwens, E., Schuurman, A. S., Akkerhuis, K. M., Constantinescu, A., Brugts, J., ... & Kardys, I. (2020). Temporal patterns of macrophage-and neutrophil-related markers are associated with clinical outcome in heart failure patients. *ESC heart failure*, 7(3), 1190-1200.
 74. Brankovic, M., Akkerhuis, K. M., van Boven, N., Anroedh, S., Constantinescu, A., Caliskan, K., ... & Kardys, I. (2018). Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. *Kidney international*, 93(4), 952-960.